Objective To develop criteria for identifying potentially inappropriate medication use (PIM) in Chinese children,with the aim of reducing the risk of adverse drug reactions (ADRs),standardizing and optimizing rational medication use,and providing a basis for helping clinicians and pharmacists rapidly identify medication-related risks in pediatric patients. Methods Methodological frameworks of existing domestic and international PIM criteria were referenced. A systematic literature search on pediatric medication safety was conducted,and pediatric ADR/ADE data reported from Sichuan Province to the National ADR Monitoring Network between 2017 and 2023 were incorporated to preliminarily formulate PIM items. Two rounds of revision were performed using the Delphi expert consultation method. The GRADE system was applied to assess the quality of evidence and strength of recommendation for all criteria. Results A total of 28 criteria were finalized,with expert consensus agreement rates exceeding 90% for all items. The criteria consist of two parts. The first part includes PIM criteria for children under non-specific conditions,covering 15 categories and 19 types of drugs. Each type of drug has 1 to 8 risk points for medication use. The second part includes PIM criteria for children under specific conditions,including disease states and concomitant medications,including 8 medication scenarios,involving 9 types of drugs or drug combinations. Each scenario has 1 to 2 risk points for medication use. Each criterion includes the drug,medication-related risk points,recommendations or alternative treatment options,supporting references,and recommendation grade. Conclusion These criteria provide a scientific and operational tool for the safety screening of pediatric medications,which helps to identify and prevent medication risks at an early stage,thereby enhancing the safety and efficacy of medication use for pediatric patients.
Objective To formulate the Expert Consensus on the Drug Selection and Evaluation System for Maternal and Child Health Care Institutions in China, including standardized drug selection processes for maternal and child health care institutions and quantitative evaluation indicators for drug variety/specification selection and manufacturing enterprise selection, so as to provide a reference for ensuring safe, effective, and economical medication for women and children. Methods A consensus development group was established. Relevant national policies,guidance documents,and published studies on drug selection and pharmacy administration were reviewed. An initial framework was developed through two steering-group meetings. Twenty-two multidisciplinary experts were invited to participate in two rounds of Delphi consultation to rate the importance of the terminal-level indicators,and the analytic hierarchy process was used to derive indicator weights. Expert authority and agreement were assessed using the authority coefficient (Cr) and Kendall's coefficient of concordance (W),respectively. Results The response rates were 100.0% and 90.9% in the two Delphi rounds,respectively,and all participating experts had Cr values greater than 0.70. The final consensus comprised a standardized selection process and two quantitative evaluation systems. The system for selecting drug varieties and specifications included five domains (19 evaluation criteria):effectiveness,substitutability,urgency of clinical need,special management requirements,and convenience of administration. The manufacturer evaluation system included five domains-accessibility,completeness of prescribing information,clinical applicability,product quality,and economic value-with 19 secondary indicators and 76 scoring criteria.The χ2 tes of Kendall's W was statistically significant (P<0.05). Kendall's W was 0.579 for the variety/specification system and 0.376 for the manufacturer system, this indicates consistency of expert opinions. Conclusion This consensus provides a structured and quantitative framework for new-drug selection,dynamic formulary management,and manufacturer evaluation in maternal and child health institutions. External validation and local calibration are required before broad implementation.
Objective To investigate the efficacy and mechanism of HY-072808 ointment in a mouse model of seborrheic dermatitis induced by Malassezia. Methods Six to eights weeks BALB/c mice weres randomly divided into blank control group,model control group,matrix group,2% ketoconazole cream group,0.05% halometasone cream group,and 1%,2%,and 4% HY-072808 ointment groups. Seborrheic dermatitis models were established by continuous application of Malassezia on the back skin for 14 days. After successful modeling,each treatment group received topical medication twice daily for 28 consecutive days,with an application dose of 15 mg∙(cm2)-1 per session. After the last administration,the back skin scores of the mice in each group were recorded,the Malassezia count in the back skin lesions was performed,the levels of IFN-γ,IL-1β,IL-2,IL-4,IL-8,and IL-17 in the serum were detected,the mRNA expression of IL-1β,IL-2,and IL-17 and the protein expression of p38 and p-p38 in the back skin lesions were detected,and the pathological changes of the skin tissue in each group were observed by HE staining. Results Compared with the model group,the erythema and scales on the back skin of mice in each drug administration group were significantly improved (P<0.05 or P<0.01),the number of Malassezia in the lesion tissue was significantly reduced (P<0.01),and the mRNA expression of IL-1β,IL-2 and IL-17 and the protein expression of p38 and p-p38 in the lesion tissue were significantly inhibited (P<0.01). The contents of IFN-γ,IL-1β,IL-2,IL-4,IL-8,and IL-17 in the serum were significantly decreased (P<0.01),and the pathological changes of the skin tissue of mice were improved to varying degrees. Conclusion HY-072808 ointment can significantly improve symptoms such as skin erythema and scales and histopathological changes in seborrheic dermatitis model mice,which is related to its inhibition of inflammatory factors and activation of the p38 MAPK pathway.
Relying on the special-access drug policies, Hainan Boao Lecheng International Medical Tourism Pilot Zone (hereinafter referred to as the Lecheng Pilot Zone) enables the rapid introduction of innovative drugs approved overseas but not registered in China, effectively filling the clinical medication gaps for severe and rare diseases in China. Taking special-licensed innovative drugs in the Lecheng Pilot Zone as the research subject, this paper sorts out their connotations, marketed varieties and policy-regulatory system through reviewing regulatory guidelines and literature, and systematically analyzes the current status of drug safety supervision across Hainan Province and within the pilot zone, as well as front-line monitoring practices in medical institutions. As a pilot for pharmaceutical regulatory reform, the Lecheng Pilot Zone has established a post-marketing safety supervision model for special-licensed innovative drugs featuring full-chain traceable closed-loop management and multi-department collaboration. Supported by differentiated special regulatory rules, it has set up dedicated adverse reaction response channels and built a pharmacovigilance mechanism covering the whole clinical use process of special-licensed innovative drugs, forming unique institutional advantages in accelerating domestic access to high-quality overseas new drugs and ensuring clinical safety of special-access medicines. Studies indicate that there is still room for improvement in multiple aspects regarding post-marketing supervision of special-licensed innovative drugs, including insufficient accumulation of real-world medication data for local patients, inadequate pharmacovigilance performance by overseas pharmaceutical enterprises, as well as imperfections in risk-stratified monitoring, professional talent pool, intelligent monitoring platforms, inter-departmental coordination and resource allocation. This paper puts forward optimization approaches covering pre-submission review, risk-stratified monitoring, institutional innovation for special pharmacovigilance, talent training, AI-driven risk-signal mining, cross-departmental data sharing and integrated resource allocation. As a test-bed for pharmaceutical regulatory reform, practical experience from the Lecheng Pilot Zone can provide referable practical insights for improving full-lifecycle supervision of local special-imported drugs and enhancing the performance of pharmacovigilance within the pilot area.
This study collated relevant policies,specifications and practical outcomes of vaccine pharmacovigilance in Australia. It focused on the development of regulatory guidelines,talent team allocation,post-marketing surveillance models,database construction and key operational points of pharmacovigilance,and summarizes experience in system operation. Combined with the current development status of vaccine pharmacovigilance in China,optimization approaches were proposed in aspects including improving laws and regulations,establishing overall coordination and management mechanisms,smoothing information communication channels,building a surveillance system integrating active and passive monitoring,deepening international cooperation,and standardizing vaccine circulation management.
Signal detection constitutes a vital component of pharmacovigilance, which can effectively identify adverse drug reaction signals. It is crucial for grasping drug safety information and safeguarding the public's medication safety. With the rapid development of medical informatization, traditional statistical and data mining methods for signal detection can no longer meet the current demands of drug supervision in the face of massive and complex multi-dimensional medical data. This paper takes pharmacovigilance signal detection-related technologies as the research object. By retrieving domestic and international thematic literature, regulatory guidelines, and practical cases, the retrieved materials were sorted out, summarized and analyzed according to technical categories. From a technical perspective, it systematically introduces the applications of artificial intelligence (AI) technologies including machine learning, natural language processing and deep learning in adverse drug reaction signal detection. AI techniques demonstrate prominent advantages in empowering adverse drug reaction signal detection. They are capable of mining information from narrative texts, transforming unstructured textual reports into structured adverse event information, and enabling multidimensional data processing. This facilitates the effective identification of potential and rare risks, thereby substantially improving the precision and efficiency of signal detection. Nevertheless, the application of AI still faces multiple challenges involving data quality, algorithm interpretability, implementation coordination, and regulatory implementation. It is recommended to optimize data governance, promote algorithm iteration and upgrading, strengthen the cultivation of professional teams, reinforce regulatory guidance, deepen international exchange and cooperation, and advance the integrated innovation of AI-based signal detection methods, thereby supporting the digital and intelligent development of drug regulation in China.
Objective To characterize the occurrence of serious adverse events (SAEs) among participants in antitumor drug clinical trials,to identify the risk factors and develop and validate a risk prediction model,and to provide a reference for safety management in clinical trials. Methods A nested case-control study was conducted using clinical data from 286 participants enrolled in antitumor drug clinical trials at a tertiary Grade A hospital in Wuhan between January 2024 and December 2025. Among them,143 participants who developed SAEs were assigned to the case group,and 143 participants without SAEs were matched 1:1 as controls. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors for SAE occurrence. A nomogram model was then developed based on the regression results and evaluated by receiver operating characteristic (ROC) curves,calibration curves,and decision curve analysis (DCA). Results Among the 143 SAE cases,hematologic disorders,digestive system diseases,and infectious diseases were the most common SAE types,with CTCAE grade 3 events predominating. Univariate analysis showed that ECOG performance status,extensive metastasis,advanced age,and AST abnormality were significantly associated with SAE occurrence (all P<0.05). Multivariate logistic regression identified ECOG performance status [OR=4.89,95%CI=(2.79,8.83),P<0.000 1],extensive metastasis [OR=2.68,95%CI=(1.47,5.01),P=0.002],and advanced age [OR=2.71,95%CI=(1.51,4.98),P=0.001] as independent risk factors for SAEs. The nomogram model showed good predictive performance,with an AUC of 0.939 in the training set and 0.884 in internal validation. Calibration curves demonstrated good agreement between predicted and observed risks,and DCA suggested favorable clinical net benefit. Conclusion The nomogram model based on ECOG performance status,extensive metastasis,and advanced age demonstrates good predictive performance for SAEs in antitumor drug clinical trials,and may assist in individualized risk assessment and early intervention.
Adult-onset Still's disease (AOSD) is a rare,polygenic,and systemic autoinflammatory disease.Its main clinical manifestations include fever,rash,arthritis,or arthralgia.As the disease progresses,various complications such as macrophage activation syndrome,disseminated intravascular coagulation,and acute respiratory distress syndrome (ARDS) may occur,posing a serious threat to the patients' lives.The etiology and pathogenesis of AOSD are still unclear,involving various factors such as genetics,infection,and immunity.Various immune cells and cytokines are directly or indirectly involved in AOSD.Currently,therapeutic drugs for AOSD include non-steroidal anti-inflammatory drugs,glucocorticoids,disease-modifying anti-rheumatic drugs,and biologics.However,their therapeutic effects are uncertain,and achieving long-term remission is challenging.Therefore,a thorough understanding of the pathogenesis of AOSD is helpful for discovering new targets and developing effective new therapeutic agents,which is of great clinical significance.This review presents recent advances in the clinical diagnosis,pathogenesis,and therapeutic drugs for AOSD.
To enhance clinicians' understanding of the rare disease adult-onset Still's disease (AOSD) by presenting a successful case of integrated traditional Chinese and Western medicine.The diagnostic and treatment process of an AOSD patient treated in the Rheumatology Department of Wangjing Hospital was reviewed.Clinical data were collected,and relevant literature was reviewed.The patient was treated with a combination of traditional Chinese and Western medicine.The Chinese medicine treatment primarily involved a modified Qinghao Biejia Decoction,with a consistent focus on replenishing qi and nourishing yin.After three months of treatment,the patient's clinical symptoms disappeared,and the patient achieved near clinical recovery.The patient has discontinued glucocorticoids and Chinese medicine for over 15 years,with no recurrence to date during follow-up.AOSD is a rare systemic autoinflammatory disease with no standardized treatment regimen currently available.Hormones or immunosuppressants are commonly used,but the condition is prone to relapse.The integrated approach of traditional Chinese and Western medicine has shown promising efficacy in treating AOSD and is worthy of clinical application and promotion.
Rheumatoid arthritis (RA) is a chronic autoimmune disease that leads to progressive joint destruction and severe functional impairment.Conventional therapeutic agents face limitations such as low specificity,significant adverse effects,and inconvenient administration routes.Microneedles (MNs),as an innovative transdermal drug delivery technology,can penetrate the stratum corneum barrier in a minimally invasive manner,enabling targeted drug delivery and controlled release,thereby offering a novel strategy for RA treatment.This review systematically summarizes the fabrication techniques,mechanisms of action,and therapeutic applications of different types of MNs in RA management.Additionally,current challenges and future directions in MN-based RA therapy are discussed.
Proteasome inhibitors regulate multiple cellular processes by inhibiting the ubiquitin-proteasome system (UPS).Currently,the proteasome inhibitors bortezomib,carfilzomib,and ixazomib have been clinically approved for the treatment of multiple myeloma and other hematological malignancies,but they still face many challenges in clinical application.In recent years,in addition to searching for new proteasome inhibitor drugs,researchers have also attempted to design and develop new formulations,including nano-formulations,to optimize their pharmacokinetic properties,reduce adverse reactions,overcome drug resistance,and even expand their indications to the treatment of solid tumors.This review introduces the mechanism of action,clinical application,and existing problems of proteasome inhibitors,and systematically summarizes the research progress of nano-formulations of proteasome inhibitors,providing important ideas for the future development of proteasome inhibitors.
Abnormal glucose metabolism refers to the disorder of the uptake,utilization,and transformation of glucose in the body,which is common in diabetes,insulin resistance,and other diseases. Hypergluconeogenesis in the liver and reduced glucose utilization in muscle and adipose tissue are also important links in abnormal glucose metabolism. Long-term abnormal glucose metabolism can cause multi-system complications such as cardiovascular,cerebrovascular,renal,and nervous systems. Exercise,diet regulation,and drug therapy are the main means to improve glucose metabolism. Recent studies have found that exercise-induced exosomes may improve insulin sensitivity and tissue glucose metabolism by delivering bioactive cargoes,including proteins,lipids,and microRNAs (miRNAs),thereby promoting glucose transporter 4 (GLUT4) translocation and modulating the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) and adenosine monophosphate-activated protein kinase (AMPK) pathway.This article reviewed the effects of exercise-induced exosomes on glucose metabolism based on the literature,providing new ideas and potential targets for interventions in abnormal glucose metabolism.
Factor VIII (FⅧ) replacement therapy is currently the main treatment for hemophilia A.The development of inhibitors against FⅧ is the most serious complication of replacement therapy.The presence of inhibitors renders replacement therapy ineffective,significantly increases the risk of bleeding,and leads to a reduced quality of life for hemophilia A patients.For the treatment and prevention of bleeding,the use of bypassing agents has been optimized in recent years;non-factor replacement therapy is also developing rapidly.Immune tolerance induction is the only treatment method for eradicating inhibitors.Quality of life monitoring is an important part of managing hemophilia A patients with inhibitors.This review summarizes the research progress in the treatment and quality of life assessment of hemophilia A patients with inhibitors,aiming to provide a reference for developing individualized treatment plans and thereby improving the health-related quality of life of hemophilia A patients with inhibitors.
Objective To optimize the decoction process conditions of Biyuanling granules and improve the quality standards of Biyuanling granules. Methods The weight coefficients of dry extract yield,baicalin content and magnolol content were determined using AHP-CRITIC method. Using the comprehensive score as the evaluation index,single factorial experiments and BBD-RSM were applied to optimize decoction times,liquid-to-material ratio,and decoction time of Biyuanling granules. The qualitative identification method for baicalin and magnolol was established. Results Under the optimal decoction process parameters (3 decoction times,liquid-to-material ratio of 11 mL∙g-1,decoction time of 2.3 h),the mean comprehensive score of Biyuanling granule extract was 94.52,with an RSD of 1.96%,which was superior to that of the extract from the original process. The TLC spectrum identified baicalin and magnolin in Biyuanling granules,which appear as dark green and purple-red spots,respectively,with no interference from negative samples. The optimized process significantly enhances the content of baicalin and magnolol in Biyuanling granules and their extract. Conclusions The application of AHP-CRITIC combined with BBD-RSM optimization to the decoction process of Biyuanling granules is stable and reliable,and the quality standards has good specificity. This provides a scientific reference for the quality control of Biyuanling granules.
Objective To prepare a dihydroavenanthramide D (DHAvD) nanoemulsion,and to investigate its in vitro transdermal properties. Methods The nanoemulsion was prepared using low-energy emulsification. The formulation process was optimized and characterized in terms of its appearance and properties. Its in vitro transdermal permeation was investigated using Franz diffusion cell. Results The particle size of the best nanoemulsion was (26.30±0.35) nm,the polydispersity index was (0.170±0.013) and the Zeta potential was (-12.76±0.29) mV. The nanoemulsion showed Tyndall effect and blue opalescence, and the droplests were shperical or elliptical shapes with good centrifugal stability. At 12 h,the intradermal retention unit area was 36.26 μg·(cm2)-1. Conclusion The fromulation process of DHAvD nanoemulsion is reasonable and the nanoemulsion can achieve effective concentration in the skin.
Objective To establish a polymorph analysis method for erythromycin and to evaluate the polymorphs in erythromycin raw material from three manufacturers. Methods Based on available literature and crystal structure data of erythromycin A,the X-ray powder diffraction (XRPD) characteristic peaks,thermal analysis data,and crystal morphology of its three polymorphs were sorted out.The raw material from different manufacturers was compared with the characteristic data of the three polymorphs of erythromycin A to evaluate the polymorphs and to establish an analytical method for erythromycin A polymorphs. Results XRPD analysis suggested that the raw material from Manufacturer A was mainly erythromycin A dihydrate,mixed with a small amount of acetonate;the raw material from Manufacturer B was mainly dihydrate,mixed with a small amount of anhydrous form;the two batches of raw material from Manufacturer C were both mixed crystals of erythromycin A anhydrous form I,anhydrous form II,and dihydrate,with different mixing ratios.Since all four batches were mixed crystals,the thermal analysis results could not fully match the data of the three polymorphs of erythromycin A.Scanning electron microscopy (SEM) analysis confirmed the XRPD results for the raw materials from Manufacturers A and B.Infrared spectroscopy and micro-Raman spectroscopy could not distinguish between different polymorphs of erythromycin A. Conclusions The combination of XRPD and thermal analysis,supplemented by SEM for confirmation,makes the results more accurate.This study has certain guiding significance for the control requirements of different polymorphs in the mass production of erythromycin raw material.
Objective To establish a working mode for drug quality monitoring and risk assessment,and to provide a reference for regulatory authorities in the supervision of high-risk drug products,by taking a PD-1 monoclonal antibody injection as an example. Methods According to the current quality standard of this product,along with domestic and international guidelines,the critical quality attributes (CQAs) of 27 batches of samples were inspected.Risk assessments focusing on the safety,stability,and controllability of the quality standard were conducted,including multidimensional studies on host cell protein residue identification using high-resolution MS,low endotoxin recovery (LER) investigations,and risk substance screening. Results All 27 batches passed the inspection of CQAs (100.00%).A risky host cell protein,phospholipase B-2 (PLBL2),was detected in all sample batches.The Fc receptor affinity of the PD-1 mAb was consistent among batches,and its FcγRI affinity suggests that glycosylation levels should be monitored during quality control.A risk of LER for this product was identified.The histidine content in each batch was close to the prescribed amount,showing minimal inter-batch variation.No risks of antibiotic residues,metallic elemental impurities,or antioxidants were found.Accelerated stability testing indicated that the CQAs of the product had no significant changes,demonstrating good stability.As to analytical methods,the results of CE-SDS purity testing using the Chinese Pharmacopoeia 2020 edition general chapter 3127 showed a statistically significant difference in non-reduced purity compared with the manufacturer's method.A novel HPLC-ELSD method was established as a potential supplement for the polysorbate 80 content test. Conclusion A risk-based working mode for the quality monitoring and risk assessment of a PD-1 monoclonal antibody injection was established.The quality of this drug is generally good.The current quality standard is basically feasible,but still requires improvement and optimization.
Objective To establish a method for the determination of dimethyl silicone oil in prefilled syringes by high-performance liquid chromatography (HPLC) with charged aerosol detector (CAD). Methods The sample was extracted with dichloromethane and measured using a ProSwift TM RP-1S chromatographic column (4.6 mm×50 mm). Gradient elution was performed using ultrapure water,acetonitrile,and tetrahydrofuran as the mobile phase,with a flow rate of 1.2 mL·min-1,column temperature of 40 ℃,and injection volume of 20 μL. Results The linear relationship of dimethyl silicone oil was good within the range of 2.5-100 μg·mL-1 (r2=0.999 5),with a detection limit of 0.625 μg·mL-1 and a quantification limit of 2.5 μg·mL-1. The repeatability and intermediate precision RSD values were both ≤1.3%,and the sample recovery rate was 96.9%~108.3%. Conclusion This method has high sensitivity and good repeatability,and provides a reliable technical solution for the quality control of dimethyl silicone oil in prefilled syringes.
Objective To systematically evaluate the migration risk of polycyclic aromatic hydrocarbons (PAHs) from label inks used on low-density polyethylene (LDPE) bottles for inhalation preparations,and to establish a scientific evaluation framework for their extraction and leaching behavior. Methods Based on gas chromatography-tandem mass spectrometry (GC-MS/MS), a simulated extraction method incorporating microwave extraction and accelerated leaching was developed.For extraction tests,a microwave method based on the chemical properties of PAHs was adopted.Combined with the accelerated leaching method simulating actual contact conditions,a leachate detection method for PAHs suitable for five types of inhalation preparations was established. Results Microwave extraction detected residual PAHs in the ink ranging from 1.665 to 2.162 ng per unit.In simulated leaching tests,the migration behavior of PAHs was affected by the polarity,ethanol content and liposolubility of the preparations.Under accelerated storage conditions (40 ℃,75% relative humidity for 6 months),none of the 17 PAHs were detected in all five inhalation preparations. Conclusion This study can provide a basis for production formulation and process control of label ink,and has application value for ensuring the safety of inhalation preparation medication.
With the acceleration of population aging, the prevalence of atopic dermatitis (AD) in the elderly (aged >60 years) has been increasing year by year, and it has become an important skin disease affecting the well-being and quality of life of the elderly in China. Elderly patients with AD often present with age-related changes such as impaired skin barrier function and immunosenescence, along with complex conditions including multimorbidity and polypharmacy, posing serious challenges to clinical diagnosis, treatment, and medication management. To standardize the clinical pharmacotherapy of geriatric AD, enhance rational drug use and pharmaceutical care, and ensure medication safety for elderly patients, the Geriatric Pharmacy Professional Committee of the Wuhan Pharmaceutical Association convened a multidisciplinary panel of experts from Hubei Province. Following evidence-based medicine principles, the panel systematically reviewed the latest domestic and international clinical studies, guidelines and consensus statements, and realworld research data, and, taking into account clinical practice in China, jointly developed the Guideline on Rational Drug Use for Atopic Dermatitis in the Elderly in Hubei Medical Institutions (hereinafter referred to as the "Guideline"). The Guideline focuses on core aspects including disease characteristics of geriatric AD, treatment principles, use of topical and systemic medications, drug selection in the presence of comorbid chronic diseases, pharmaceutical care, and longterm followup, aiming to provide scientific and practical medication guidance for healthcare professionals at all levels of medical institutions.
Objective To construct and verify population pharmacokinetic (popPK) models of vancomycin in adult patients with hematological malignancies and bloodstream infection. Methods Clinical data of adult patients with hematological malignancies and bloodstream infection treated with vancomycin from December 2019 to December 2024 were retrospectively collected. The popPK model was developed based on a one-compartment structural model,with an exponential model for interindividual variability and an additive model for intraindividual variability. Covariates influencing vancomycin clearance (CLVAN) and apparent volume of distribution (VVAN) were identified using the “forward inclusion and backward elimination” approach. Model performance was evaluated using goodness-of-fit plots and Bootstrap analysis. Results Data from 31 patients were analyzed. Creatinine clearance (CLcr) and procalcitonin (PCT) were identified as covariates for CLVAN,while age and PCT influenced VVAN. The popPK models were:CLVAN=4.16×(PCT/2.46)-0.21× (CLcr/111.09)0.47,VVAN=33.71×(Age/51.58)-1.42× (PCT/2.46)-0.68,and had acceptable predictive performance. Conclusions This study established a popPK model of vancomycin for adult patients with hematological malignancies and bloodstream infection. The model can serve as a basis for preliminary pharmacokinetic evaluation in this specific population and holds clinical and population-specific significance.
A 63-year-old male patient underwent open reduction and internal fixation of the right lateral malleolus fracture under spinal anesthesia.Postoperatively,the patient was administered ketorolac tromethamine injection,famotidine injection,and mannitol injection.On the third day after surgery,the patient developed liver function abnormalities.An adverse drug reaction induced by ketorolac tromethamine injection was suspected,so the drug was immediately discontinued and hepatoprotective treatment was given.Liver function tests rechecked on May 7, 2023, showed improvement compared to previous results. This article evaluates the causality of this adverse reaction to ketorolac tromethamine injection and analyzes the possible mechanisms of this adverse drug reaction based on literature review.It is recommended that when using ketorolac tromethamine injection clinically,liver function indicators should be regularly monitored to improve patient medication safety.
Objective To analyze the price change trends and reasons for therapeutic monoclonal antibodies (mAbs) marketed in China from 2014 to 2024,and to provide a reference for improving the innovative drug pricing mechanism. Methods A catalog of therapeutic mAbs marketed in China from 2014 to 2024 was established,along with the average winning bid prices from centralized procurement by provincial medical institutions.The compound annual growth rate (CAGR) was calculated. Results By the end of 2024,123 therapeutic mAbs were marketed in China.The average price per package unit of marketed mAbs as a proportion of the per capita disposable income of middle-income households decreased from 42.21% in 2014 to 22.34% in 2024.Among PD-1 and PD-L1 targeting mAbs,the prices of four mAbs produced by domestic companies decreased,while the prices of four mAbs produced by foreign companies remained unchanged.Overall,the average prices of mAbs produced by domestic and foreign companies were RMB 3 728.66 and RMB 10 143.24,respectively,with average CAGRs of -24.28% and -22.39%.The average CAGRs for originator mAbs and biosimilars were -14.32% and -3.49%,respectively.The average price reduction for 31 mAbs included in the national basic medical insurance directory through price negotiation was 62.05%. Conclusions Factors such as the rapid increase in the number of mAb biosimilars and originators marketed by domestic companies,and the implementation of national medical insurance price negotiation policies have contributed to a significant decline in the prices of most mAbs in China.However,the price reductions for some originator mAbs from overseas companies with high clinical value have been modest.To promote the affordability of mAbs for patients and the development of industrial innovation in China,it is still necessary to improve the value-based drug pricing mechanism and the multi-party co-payment model.
Objective To evaluate current practices and challenges in whole-process management of narcotic and psychotropic drugs across tertiary hospitals in Jiangsu Province,China,thereby enhancing regulatory compliance for controlled medications. Methods A structured questionnaire was developed to evaluate whole-process management practices,with validity verified through expert review. Using the Questionnaire Star platform,an online survey was administered to pharmacists across 60 tertiary hospitals in Jiangsu Province. Data analysis employed descriptive statistics and content analysis. Results The survey yielded 104 valid responses from 130 distributed questionnaires (effective response rate:80%). Results demonstrated substantial regulatory compliance in core management areas,while revealing persistent challenges in four key domains:information management systems,personnel allocation adequacy,operating room narcotic pharmacy infrastructure,and control measures for Schedule II psychotropic substances. Conclusion Healthcare institutions should implement enhanced digital tracking systems for controlled medications,prioritize the development of operating room narcotic pharmacy infrastructure,and optimize control procedures to elevate management standards.
Objective To analyze the accessibility of hypoglycemic drugs in Shanxi Province,and to explore the impact of drug policies on the accessibility of hypoglycemic drugs and the structure of drug use in Shanxi Province. Methods Using a stratified random sampling method,drug procurement data from 2017 to 2022 were extracted from 18 medical institutions at different levels in Shanxi Province according to economic development levels.Descriptive statistical methods were used to describe drug accessibility based on indicators such as allocation rate,availability rate,defined daily doses (DDDs),and defined daily dosecost (DDDc).Linear regression analysis was performed to explore the trends in drug use and cost. Results After 2020, the availability rate of hypoglycemic drugs stocked by the surveyed institutions and the accessibility rate of novel hypoglycemic drugs have gradually increased;the drug stocking rate and usage volume in primary healthcare institutions are both lower than those in secondary and tertiary healthcare institutions;from 2017 to 2022, the total DDDs of hypoglycemic drugs increased from 2 974 723.60 to 8 159 992.37, showing an overall upward trend in use;the proportion of some novel hypoglycemic drugs used has increased year by year, but insulin and its analogues and oral hypoglycemic drugs remain the most frequently used drugs;the average defined daily dose cost (DDDc) of hypoglycemic drugs showed a downward trend (B=-2.88,P<0.05);and the usage volume of bid-winning drugs increased as DDDc decreased. Conclusions The implementation of drug policies has improved drug accessibility,but the overall level still needs to be enhanced.There are differences in the usage trends of different categories of drugs.It is necessary to continuously pay attention to clinical medication use and further strengthen the guarantee of drug supply.
Objective To understand the current status and development trends of registered clinical trials for migraine drugs in China,and to provide data support for sponsors,researchers,and regulatory authorities. Methods On the Drug Clinical Trial Registration and Information Platform of the National Medical Products Administration (NMPA),using “migraine” as keywords in both Chinese and English,information on registered clinical trials for migraine drugs from November 2012 (platform launch) to September 2024 was retrieved.Data including registration time,drug name,dosage form,drug classification,indication,trial phase,research progress,design type,lead unit,and sponsor were collected and analyzed using Microsoft Office Excel. Results A total of 75 registered clinical trials for migraine drugs were retrieved,including 22 domestic multi-center trials,43 domestic single-center trials,and 10 international multi-center trials.Regarding trial phases,there were 12 phase I trials (16.0%),11 phase II trials (14.7%),24 phase III trials (32.0%),and 28 bioequivalence trials (37.3%).The drug classification involved 48 chemical drugs,12 biological products,and 15 traditional Chinese medicine/natural drugs.In terms of dosage forms,there were 12 injections,25 tablets,7 orally disintegrating tablets,23 capsules,2 granules,and 6 nasal sprays. Conclusions The lead units for registered clinical trials of migraine drugs in China are mainly concentrated in regions with advanced medical resources.The number of trials for drugs targeting new targets,such as calcitonin gene-related peptide (CGRP) receptor antagonists and monoclonal antibodies targeting CGRP and its receptor (CGRPR),is increasing year by year.Most of these drugs are in the research and development stage and have not yet been approved for marketing in China,and their efficacy in the Chinese population needs further verification.